Recent Company News

• 07:25 AM ET Mar 20, 2025
  

  Barinthus Biotherapeutics reports FY EPS ($1.55) vs FactSet ($1.48) [3 est, ($1.67)-(1.32)] ($0.99, 0.00)

• 08:10 AM ET Jan 10, 2025
  

  Barinthus Biotherapeutics announces strategic focus in immunology and inflammation; provides financial update ($1.14, 0.00)

• 04:04 PM ET Nov 25, 2024
  

  Barinthus Biotherapeutics Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer ($0.98, 0.00)

• 11:11 AM ET Nov 15, 2024
  

  Barinthus Bio announces results from ongoing Phase 2B Chronic Hepatitis B trial, including achievement of functional cure and HBsAb seroconversion ($1.36, -0.02)

• 11:03 AM ET Nov 15, 2024
  

  Barinthus Biotherapeutics announce new data from the IM-PROVE II trial showing that the addition of Nivolumab increased rates of HBsAg loss in people with chronic hepatitis B ($1.32, -0.06)

• 08:04 AM ET Nov 06, 2024
  

  Barinthus Biotherapeutics reports Q3 EPS ($0.21) vs year-ago ($0.37) ($1.34, 0.00)

• 08:12 AM ET Oct 31, 2024
  

  Barinthus Biotherapeutics announces updated clinical data from its chronic hepatitis B program will be highlighted at AASLD ($1.43, 0.00)

• 08:02 AM ET Oct 01, 2024
  

  Barinthus Bio completes Enrollment for Phase 2B HBV003 trial in chronic hepatitis B and Phase 1 PCA001 trial in prostate cancer ($1.19, 0.00)

• 08:01 AM ET Sep 24, 2024
  

  Barinthus Biotherapeutics initiates Phase I clinical trial of VTP-1000 for the treatment of celiac disease ($1.20, 0.00)

• 04:12 PM ET Sep 05, 2024
  

  Barinthus Biotherapeutics appoints Graham Griffiths as COO effective 1-Sep-24 - 8-K ($1.23, 0.00)